Academic Journal
Paediatric non-rhabdomyosarcoma soft tissue sarcomas. The prospective NRSTS 2005 study by the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)
| العنوان: | Paediatric non-rhabdomyosarcoma soft tissue sarcomas. The prospective NRSTS 2005 study by the European pediatric Soft Tissue Sarcoma Study Group (EpSSG) |
|---|---|
| المؤلفون: | Andrea Ferrari, Max M van Noesel, Bernadette Brennan, Ilaria Zanetti, Nadege Corradini, Michela Casanova, Pablo Berlanga, Johannes H M Merks, Rita Alaggio, Stefan Schifflers, Gema L Ramirez-Villar, Chiara Giraudo, Gabriela Guillen Burrieza, Akmal Safwat, Gianni Bisogno, Gian Luca De Salvo, Daniel Orbach |
| المساهمون: | Ferrari, Andrea, M van Noesel, Max, Brennan, Bernadette, Zanetti, Ilaria, Corradini, Nadege, Casanova, Michela, Berlanga, Pablo, M Merks, Johannes H, Alaggio, Rita, Schifflers, Stefan, L Ramirez-Villar, Gema, Giraudo, Chiara, Guillen Burrieza, Gabriela, Safwat, Akmal, Bisogno, Gianni, Luca De Salvo, Gian, Orbach, Daniel |
| سنة النشر: | 2021 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: | paediatric non-rhabdomiosarcoma chemotherapy |
| الوصف: | ackground: A standardised approach to treatment of paediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), which account for about 4% of childhood cancers, is still lacking. We report the results of the NRSTS 2005 protocol developed specifically by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) to determine a risk-adapted multimodal standard of care for this group of tumours. Methods: The EpSSG NRSTS 2005 study included two prospective, non-randomised, historically controlled trials (one on localised adult-type NRSTS and the other on localised synovial sarcoma) done at 100 academic centres and hospitals in 14 countries. Patients younger than 21 years with a pathologically proven diagnosis of synovial sarcoma or an adult-type NRSTS, no evidence of metastatic disease, no previous treatment other than primary surgery, and diagnostic specimens available for pathological review were included. Patients were stratified by surgical stage, tumour size, nodal involvement, tumour grade (for adult-type NRSTS), and tumour site (for synovial sarcoma). Patients were then divided into four treatment groups: surgery alone, adjuvant radiotherapy, adjuvant chemotherapy (with or without radiotherapy), or neoadjuvant chemotherapy (with or without radiotherapy). The main chemotherapy regimen was ifosfamide (3·0 g/m2 intravenously per day for 3 days) plus doxorubicin (37·5 mg/m2 intravenously per day for 2 days); only ifosfamide (3·0 g/m2 intravenously per day for 2 days) was given concomitantly with radiotherapy (delivered with three-dimensional conformal external beam technique, using conventional fractionation [1·8 daily fractions, 5 days per week] at a dose of 50·4 Gy or 54·0 Gy, to a maximum of 59·4 Gy). The number of chemotherapy cycles ranged from three to seven depending on the stage of the disease. The primary outcomes were event-free survival and overall survival. This study has been completed, and is registered under EudraCT, 2005-001139-31. Findings: Between May 31, 2005, and Dec 31, 2016, 1321 ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/34214481; info:eu-repo/semantics/altIdentifier/wos/WOS:000677655700014; volume:5; issue:8; firstpage:546; lastpage:558; numberofpages:13; journal:THE LANCET CHILD & ADOLESCENT HEALTH; https://hdl.handle.net/11573/1704305 |
| DOI: | 10.1016/S2352-4642(21)00159-0 |
| الاتاحة: | https://hdl.handle.net/11573/1704305 https://doi.org/10.1016/S2352-4642(21)00159-0 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.22C72E19 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S2352-4642(21)00159-0 |
|---|